EUVIMEDEUVIMED entdecken
Crossref

HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia

Luca Russo, Marta Sampietro, Marco Cellani, Federica Barbaglio, Francesca Vittoria Sbrana, Giorgio Barigelletti, Jessica Bordini, Dafne Barozzi, Anna Sofia Tascini, Riccardo Campanile, Valeria Cassina, Francesco Mantegazza iD und 2 weitere

Journal of Leukocyte Biology · 2026

DOI: 10.1093/jleuko/qiag099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2026. Verfasst von Luca Russo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Malignant B Cells Biology and 3D Modelling Unit, Division of Experimental Oncology, Comprehensive Cancer Centre, IRCCS Ospedale San Raffaele, Via Olg…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Cytoskeleton, Protein Kinase Inhibitors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Unidad de Microscopía e Imagen Dinámica de CNIC, European Union NextGenerationEU/PRTR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is a B cell malignancy driven by aberrant signaling and microenvironmental support. Cytoskeletal remodeling contributes to these mechanisms, where the hematopoietic protein HS1 appears to play a key role. Thus, we generated C57BL/6 HS1 knockout (HS1KO) mice to assess its impact on lymphocyte development. Young HS1KO mice showed some alterations in B cell maturation and T cell differentiation, which appeared to normalize with age. In double-transgenic Eμ-TCL1-HS1KO mice, combining HS1 loss with the standard Eμ-TCL1 CLL mouse model, we observed a trend of reduction in the CD4/CD8 ratio, and disrupted splenic architecture with loss of follicular organization. Transcriptomic and kinase profiling of the human CLL cell line MEC1, in which HS1 was knocked out (MEC1-HS1KO), revealed a coherent impairment in terms of cell mobility as highlighted by severely impaired migration in 2D and 3D environments, reduced chemotactic responses to CXCL12 and CCL19; deregulation of cytoskeletal, adhesion, and apoptotic pathways; and increased resistance to apoptosis. We posited that these defects could reduce sensitivity to BTK (Bruton's tyrosine kinase) inhibition, a standard therapeutic approach in CLL. Primary CLL cells from the spleen of Eμ-TCL1-HS1KO mice appeared to show reduced sensitivity to ibrutinib, a finding that was also observed in adoptive transfer experiments designed to equalize disease burden. Wild-type mice receiving Eμ-TCL1-HS1KO leukemic cells tend to be more resistant to ibrutinib, particularly in the peripheral blood and spleen. All together, these findings establish HS1 as a potential regulator linking B cell receptor signaling, cytoskeletal remodeling, leukemic progression, and response to therapy, supporting its potential as a biomarker for BTK inhibitor sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAgammaglobulinaemia Tyrosine KinaseCytoskeletonProtein Kinase InhibitorsAnimalsHumansMiceMice, KnockoutPiperidinesMice, Inbred C57BLAdeninePyrazolesApoptosisPyrimidinesB-LymphocytesCell Line, Tumor

Stichwörter der Autor:innen

BTK inhibitorHS1cell motilitychronic lymphocytic leukemiadrug sensitivity

Substanzen

Agammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPiperidinesBtk protein, mouseAdeninePyrazolesPyrimidinesibrutinibBTK protein, human

Autor:innen und Institutionen

  • Malignant B Cells Biology and 3D Modelling Unit, Division of Experimental Oncology, Comprehensive Cancer Centre, IRCCS Ospedale San Raffaele, Via Olgettina 58, Milan 20132, Italy.
  • B-cell Neoplasia Unit, Comprehensive Cancer Centre, IRCCS Ospedale San Raffaele, Via Olgettina 58, Milan 20132, Italy.
  • Center for Omics Sciences, IRCCS Ospedale San Raffaele, Via Olgettina 58, Milan 20132, Italy.
  • BioNanoMedicine Center, School of Medicine and Surgery, Università di Milano-Bicocca, Via Raoul Follereau 3, Vedano al Lambro (MB) 20854, Italy.
  • School of Medicine, Università Vita-Salute San Raffaele, Via Olgettina 60, Milano 20132, Italy.

ORCID-Profile: Francesco Mantegazza, Cristina Scielzo

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Unidad de Microscopía e Imagen Dinámica de CNIC
  • European Union NextGenerationEU/PRTR

Zitieren

APA

Russo, L., Sampietro, M., Cellani, M., Barbaglio, F., Sbrana, F. V., Barigelletti, G., Bordini, J., Barozzi, D., Tascini, A. S., Campanile, R., Cassina, V., Mantegazza, F., Ghia, P., & Scielzo, C. (2026). HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiag099

Vancouver

Russo L, Sampietro M, Cellani M, Barbaglio F, Sbrana FV, Barigelletti G, et al. HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia. Journal of Leukocyte Biology. 2026. doi:10.1093/jleuko/qiag099

BibTeX
@article{Russo2026,
  author = {Russo, Luca and Sampietro, Marta and Cellani, Marco and Barbaglio, Federica and Sbrana, Francesca Vittoria and Barigelletti, Giorgio and Bordini, Jessica and Barozzi, Dafne and Tascini, Anna Sofia and Campanile, Riccardo and Cassina, Valeria and Mantegazza, Francesco and Ghia, Paolo and Scielzo, Cristina},
  title = {HS1 loss drives cytoskeletal dysregulation and reduces sensitivity to BTK inhibition in chronic lymphocytic leukemia},
  journal = {Journal of Leukocyte Biology},
  year = {2026},
  doi = {10.1093/jleuko/qiag099}
}
Kostenlos starten →